Xeris Pharmaceuticals

Executive Summary

Xeris Pharmaceuticals is a biopharmaceutical company specializing in ready-to-use injectable formulations using its proprietary XeriSol and XeriJect platforms. The company has commercial products in endocrinology and neurology and a pipeline of 19 drug candidates. Recent clinical activity includes completed Phase 2 trials for levothyroxine sodium in hypothyroidism and Phase 3 trials for glucagon products in hypoglycemia. With a strong formulation technology and collaborations with pharmaceutical partners, Xeris is positioned to expand its portfolio. The company's valuation exceeds $1 billion, reflecting market confidence in its pipeline and commercial execution. Near-term growth hinges on advancing pipeline candidates and securing regulatory approvals for new indications.

Upcoming Catalysts (preview)

• Q3 2026NDA submission for levothyroxine sodium ready-to-use injectable60% success
• TBDNew partnership or licensing deal for XeriSol/XeriJect platform70% success
• Q4 2026Initiation of Phase 3 trial for G-Pump or other glucagon product in new indication50% success